Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?
Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.
Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.
This eBook provides scientists with more information on antibody–drug conjugates (ADCs), allowing you to further your research in this field.
Touchlight, a UK-based custom development and manufacturing organization (CDMO) specializing in enzymatic DNA production, signed a license agreement with British drugmaker GSK which grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA (doggybone DNA) technology for the development and production of mRNA-based products.
Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.
With the advent of advanced chromatographic methods, researchers can now delve into the intricacies of biological samples with unparalleled precision.
This article collection hopes to provide scientists with more information on biopharmaceutical analytics allowing you to further your research in biomanufacturing.
Kyowa Kirin announced a new, state-of-the-art manufacturing facility in Sanford, North Carolina, US. Kyowa Kirin will invest up to $530 million (€489 million) in constructing a 15,951m2 two-bioreactor facility, scheduled to break ground in Q3 of 2024.
Aurigene Pharmaceutical Services Limited (Aurigene), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 6500 m2 (70,000 sq ft) in Hyderabad, India.
Ori Biotech a cell and gene therapy (CGT) manufacturing technology producer, recently announced the commercial launch of IRO, a next-generation platform.
Enzene Biosciences, a global CDMO announces the launch of a new Drug Discovery Division.
On Monday, Paris-based French drugmaker Sanofi announced plans to invest more than €1 billion at three facilities in France to create new bioproduction capacity.
Life science group Sartorius and biopharmaceutical firm Sanofi are partnering to create a platform for continuous downstream bioprocessing. Sartorius will use its engineering and manufacturing skills to commercialize integrated and continuous biomanufacturing (ICB) platforms, using Sanofi’s prototypes. In exchange, Sanofi will provide Sartorius with exclusive access to its ICB platform knowledge and patents.
Download this complimentary Expert Insights eBook today!
This Expert Insights eBook is designed to enhance scientists’ understanding of qPCR for cell and gene therapy, enabling further research in the field of drug discovery and development.
Aragen, a CRDMO, has launched the first phase of its biologics manufacturing facility in Bangalore, India. The $30 million project, executed by its subsidiary Aragen Biologics Pvt Ltd, has completed its first small-scale manufacturing project for a US-based organization, producing a novel anticancer monoclonal antibody.
Greentech firm Afyren Neoxy, a subsidiary of Afyren, received a €3.4 million payment this week for achieving key milestones with its bio-based low-carbon products.
Evonik Vland Biotech, a new joint venture between Evonik China and Shandong Vland Biotech, began operations on January 1, 2024. The venture aims to expand the market presence of their livestock probiotics in Greater China and develop new products. The official opening took place in Qingdao on March 14.
Epsilogen and Lonza have successfully completed the manufacturing of a potential cancer treatment. The complex process, which took less than ten months, was carried out at Lonza’s UK site following Good Manufacturing Practice (GMP) standards.
This Article Collection aims to offer scientists a wealth of information on monoclonal antibody (mAb) therapy, enabling you to advance your research in this field.
Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and biotechnology, recently announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.
In response to the urgent need for sustainable solutions in the surfactants industry, companies like Locus Ingredients are developing environmentally friendly biosurfactants.
The biopharmaceutical industry is experiencing a drive towards biologic products due to their promise as treatments for chronic diseases.
The pharmaceutical market is undergoing a profound transformation, driven by innovation among biologics and advanced therapies (ATs). This shift is not only redefining the treatment landscape but also presenting new opportunities and challenges related to the drug development and manufacturing value chain.
The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven these capabilities over the past two years by producing Covid-19 vaccines and a significant number of clinical batches for several biological companies. By investing in its competencies, capacities and flexibility, the company intends to further expand this demanding but promising business area.
Science and technology group 3M has announced plans to invest $146 million to expand its biopharma filtration capabilities at manufacturing facilities in Europe. The company did not disclose the facilities’ locations.
Swiss CDMO Siegfried has acquired a 95% stake in Dinamiqs, a compatriot biotech focused on developing and manufacturing viral vectors for cell and gene therapies.
Germany’s Merck said this week it has signed a non-binding Memorandum of Understanding (MoU) with South Korea’s Ministry of Trade, Industry and Energy (MOTIE), and Daejeon City to establish a new Asia-Pacific BioProcessing Center.
Purolite, a US manufacturer of ion exchange resins that is also part of Ecolab, has opened up a new facility in Llantrisant, Wales, tripling its bioprocessing resin production. The company said the extra output will meet growing global demand for biopharmaceutical products.
